ClinicalTrials.gg
Status unknownNCT00197834Updated Aug 15, 2006

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

A Phase 1 interventional study of Depakote in Dementia, sponsored by Hearthstone Alzheimer Care. Status unknown at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2006-08-15.

Sponsored by Hearthstone Alzheimer Care · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2005), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,050 studies in Dementia with a site in United States — 212 open to participants now, 277 under way, 15 of them phase 3. Dementia · United States.

Enrollment
706th of 846
20 · median 94
Started
2004
with 12 others
Phase 1
50 of 1,050
8 open now
Registered
54th of 1,050
by date

Among the 1,050 studies in Dementia with a site in United States, this one is the 706th largest by enrollment of the 846 interventional ones that give a count, is one of 13 that started in 2004, is one of 50 in phase 1, and was the 54th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

212 of the 1,050 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,050 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a 6-week period among patients with elevated scores on those scales, and that these positive results can be achieved with fewer side effects than with other agents. In addition, patients will be rated with respect to changes in the Clinical Global Impression (CGI) at baseline, week 1, 3, and 6 and the Neuropsychiatric Inventory (NPI) at baseline and week 6.

Read the detailed description

This open label, naturalistic study will enroll a total of 20 patients who are being treated for Behavioral and Psychological Symptoms of Dementia (BPSD), and who are being newly tried on Depakote in either the ER or sprinkle formulation. Patients who are suitable for study inclusion will have a score of at least 4 (out of 5, with 5 being the most severe) on at least one item (verbal agitation, physical agitation, and or aggression) of the Cohen-Mansfield Agitation Inventory (CMAI), short form. In this study Depakote ER will be prescribed in addition to existing pharmacotherapy; there will be no washout of co-prescribed psychotropic agents. The study will not seek to enroll equal numbers of patients on Depakote only vs. concomitant treatment. Study subjects will be recruited in multiple assisted living, nursing home and hospital sites in Massachusetts. We anticipate that they will roughly mirror the age, gender, and other demographic distribution of the larger SCU population. This will be a rolling enrollment as patients present with symptoms appropriate for this treatment. Our estimate is based on past experience with the referral rates for medication evaluation from these sites. Patients currently on atypical antipsychotics who have residual BPSD will be considered for the study, as will those on acetylcholinesterase inhibitors. Our logic is that as prescribed, these agents are not having the desired effect in reducing BPSD. Patients who are taking, and are appropriate to remain on, conventional antipsychotics will be excluded from the study. For each enrolled patient we will obtain baseline a psychiatric and medical assessment; results of the Mini Mental Status Evaluation (MMSE), CMAI, NPI - NH version and CGI; and a nursing staff patient status report prior to beginning psychotropic medication. These will be completed at time of study enrollment. Patients will then be followed for six weeks, with valproic acid levels drawn at weeks 1,3, and 6. Nursing staff will complete the CMAI at baseline and at weeks 1, 3, and 6. Physicians will score patients on the CGI at baseline, week 1, 3, and 6, and Clinical Raters will complete the NPI at baseline and week 6.

03

Conditions studied

  • Dementia

Keywords

  • Depakote
  • Agitation
  • Dementia
  • Atypical antipsychotic
  • Behavioral Symptoms
  • Psychiatric Symptoms
  • Psychological Symptoms
  • Geriatric
  • Behavioral and Psychological Symptoms
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Fourth Edition (DSM-IV) dementia diagnosis
  • Age > or = 60 years
  • > 7
  • Clinical evidence of a behavioral disturbance as evidenced by nursing staff report or mean score of > 4 on at least one CMAI item
  • May be on and remain on co-prescribed psychotropic agents (e.g., antidepressants, atypical antipsychotics, acetylcholinesterase inhibitors)

Exclusion criteria

Exclusion Criteria:

  • Patients with schizophrenia, bipolar disorder, seizure disorder that are co-morbid with dementia
  • Patients with delirium, or a poorly controlled medical illness
  • > 24
  • Lack of a significant behavioral disturbance
  • Low count
  • Liver function tests (LFTs) > 2x normal
  • Currently on a Depakote formulation or prior unsuccessful trial of Depakote
  • Currently on lamotrigine (Lamictal)
  • Not currently on but intends to initiate treatment with an acetylcholinesterase inhibitor or memantine during the course of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline on CMAI sub-scales

  2. Blood levels of effective dose

Secondary outcomes

  1. Change from baseline on CGI and NPI

  2. Dosing information on Concomitant psychotropic medications

  3. Adverse effects and tolerability

07

Study locations

1 of 1 sites recruiting
  • Hearthstone at Golden Pond
    Hopkinton, Massachusetts 01748, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00197834
Lead sponsor
Hearthstone Alzheimer Care
Collaborators
Abbott
First posted
Sep 20, 2005
Start date
Mar 2004
Last update
Aug 15, 2006

Study contacts

Joan Hyde, Ph.D.
Contact
hyde@thehearth.org
781-674-2884 ext. 30
Mark Vanelli, MD
principal investigator · Hearthstone Alzheimer Care
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion